Background Hereditary angioedema (HAE) is a rare disease characterized by
unpredictable, potentially life-threatening attacks, resulting in significant physical and …

Hereditary Angioedema (HAE) is a rare and disabling disease for which early diagnosis and
effective therapy are critical. This revision and update of the global WAO/EAACI guideline on …

Background ACEi medications were developed after it was noted that people bitten by the
Brazilian pit viper Bothrops jararaca developed profound hypotension and frequently died …

Background Hereditary angioedema is characterized by recurrent and unpredictable
swellings that are disabling and potentially fatal. Selective inhibition of plasma prekallikrein …

Background Hereditary angioedema is associated with dysregulation of the kallikrein–kinin
system. Factor XII (FXII) is a key initiator of the kallikrein–kinin system, which produces …

Background Hereditary angioedema is a rare and potentially life-threatening genetic
disease that is associated with kallikrein–kinin system dysregulation. Garadacimab …

Background The aim was to evaluate long‐term effectiveness and safety of lanadelumab in
patients≥ 12 y old with hereditary angioedema (HAE) 1/2 (NCT02741596). Methods …

Background Berotralstat (BCX7353) is an oral, once‐daily inhibitor of plasma kallikrein
recently approved for prevention of angioedema attacks in adults and adolescents with …

Background Hereditary angioedema (HAE) is a rare genetic disease with significant
morbidity and mortality for which early diagnosis and effective therapy are critical. Many Asia …

Background Berotralstat (BCX7353) is a recently approved, oral, once-daily kallikrein
inhibitor for hereditary angioedema (HAE) prophylaxis. In the APeX-2 trial, berotralstat …